You are here

Merus

FDA delays decision on Merus' first-in-class cancer drug by 3 months

Fierce Biotech

Tue, 11/5/24 - 10:03 am

Top ten biopharma R&D deals of 2024

Nature

Wed, 06/5/24 - 11:24 am

Argo Biopharmaceutical

MOMA Therapeutics

Boehringer Ingelheim

Suzhou Ribo Life Science

Isomorphic Labs

Gilead Sciences

Umoja Biopharma

Caris Life Sciences

Voyager Therapeutics

ASCO24 preview: A look at some of the cancer meeting’s hottest abstracts

BioSpace

Fri, 05/31/24 - 11:03 am

Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab

Fierce Biotech

Wed, 03/6/24 - 11:30 am

Gilead Sciences

ASCO: Merus' gene-targeting cancer drug shrinks tumors. Will execs go it alone or partner?

Fierce Biotech

Tue, 06/7/22 - 10:16 am

NRG1 fusion-positive cancer

#ASCO21: Eli Lilly-partnered Merus reveals new data for NRG1 fusion cancers including pancreatic and NSCLC

Endpoints

Sat, 06/5/21 - 02:17 pm

clinical trials

Eli Lilly tees up discovery pact worth more than $1.6B with Merus for T cell-focused bispecific antibodies

Endpoints

Tue, 01/19/21 - 10:39 am

Merus charts early promise for cancer drug targeting NRG1 fusions

Fierce Biotech

Mon, 10/28/19 - 10:40 am

bispecific antibodies

4 Stocks Battling Breast Cancer

Motley Fool

Sat, 10/26/19 - 02:18 pm

Seattle Genetics

Top Presentations to Look for at ASCO

Yahoo/24-7 Wall St

Tue, 05/30/17 - 11:35 am

Juno Therapeutics

Incyte puts up $200M in bispecifics deal with Merus

BioPharma Dive

Thu, 12/22/16 - 10:21 am

bispecific antibodies

Big Pharma-backed Dutch immuno-oncology player eyes €100M Nasdaq IPO

Fierce Biotech

Thu, 04/9/15 - 10:01 am

immuno-oncology

J&J makes an R&D splash with $42M venture play, biotech collaborations

Fierce Biotech

Thu, 10/3/13 - 05:35 pm

Novartis Venture Fund

Pfizer Venture Investments